Spyre Therapeutics
SYRE
103 hedge funds and large institutions have $1.21B invested in Spyre Therapeutics in 2024 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 6 closing their positions.
817% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 6
102% more capital invested
Capital invested by funds: $601M → $1.21B (+$612M)
91% more funds holding
Funds holding: 54 → 103 (+49)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
602.06% less ownership
Funds ownership: 691.63% → 89.57% (-602%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$81.1M |
| 2 |
YF
Yu Fan
|
+$21.4M |
| 3 |
BlackRock
New York
|
+$15.6M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$13.7M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$21.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$19.9M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$19.1M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$14.8M |
| 5 |
GEM
Global Endowment Management
Charlotte,
North Carolina
|
-$14.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
JP Morgan Chase
New York
| $417 | -$869 | -30 | -73% |
|
|
PCWA
102
Pacific Capital Wealth Advisors
Corona,
California
| $303 | – | – | – |
|
103
Macquarie Group
Sydney, NSW 2000,
Australia
| $96 | +$73.1K | +2,523 | New |
|
|
EC
104
EcoR1 Capital
San Francisco,
California
| – | -$19.1M | -887,076 | Closed |
|
|
BI
105
BVF Inc
San Francisco,
California
| – | -$14.8M | -687,080 | Closed |
|
|
UONDDL
106
University of Notre Dame du Lac
South Bend,
Indiana
| – | -$12.4M | -577,616 | Closed |
|
|
PM
107
Prosight Management
Dallas,
Texas
| – | -$1.18M | -55,000 | Closed |
|
108
Acadian Asset Management
Boston,
Massachusetts
| – | -$25K | -1,169 | Closed |
|
|
PA
109
Parallel Advisors
San Francisco,
California
| – | -$22 | -1 | Closed |
|
SYRE Hedge Fund Activity: Q1 2024 in Review
103 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2024, worth a combined $1.21B — up 102% from $601M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new SYRE positions and 6 closed out — a net gain of 49 holders — while 20 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $81.1M. The largest seller was Deep Track Capital, cutting an estimated $21.4M.
- 103 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2024, up from 54 in Q4 2023.
- Funds reported $1.21B of Spyre Therapeutics stock for Q1 2024, up 102% quarter-over-quarter.
- 55 funds opened new Spyre Therapeutics positions in Q1 2024 and 6 closed out, a net change of +49 holders.
- The largest Spyre Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $81.1M added.
- The largest Spyre Therapeutics seller in Q1 2024 was Deep Track Capital, an estimated $21.4M sold.
Based on aggregated 13F filings for Q1 2024.